Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia

Robin R. Vann, Carol L. Karp

Research output: Contribution to journalArticlepeer-review

116 Scopus citations


Objective: To evaluate the role of combined subconjunctival and topical interferon alfa-2b (IFNα2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN). Design: Noncomparative case series. Participants: Six patients with histologically proven CIN or recurrences of histologically proven CIN were studied prospectively. Intervention: Patients were given a single subconjunctival/perilesional injection of recombinant IFNα2b (Schering Plough, Kenilworth, NJ) 3 million international units (IU) in 0.5 ml and then started receiving topical interferon drops (1 million U/ml) four times a day. Patients were followed weekly until complete resolution of the tumor. After 1 week, patients with minimal response while receiving topical therapy were retreated with perilesional injections three times a week until resolution. Patients received topical interferon drops for a month after clinical resolution of the lesion. Main Outcome Measures: Patients were followed clinically and photographically for evidence of tumor resolution. Results: The authors present a series of six patients who were treated successfully with a combination of subconjunctival/perilesional and topical IFNα2b. All six patients had complete clinical resolution of the CIN lesion within 6 weeks of initiation of treatment. In the time of follow-up (average, 7.2 months; range, 2-11 months), there have been no treatment failures or recurrences. Conclusion: IFNα2b may be a viable medical alternative to surgical excision for primary or recurrent CIN.

Original languageEnglish (US)
Pages (from-to)91-97
Number of pages7
Issue number1
StatePublished - Jan 1 1999

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia'. Together they form a unique fingerprint.

Cite this